Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Universal Biosensors, Inc.
  6. News
  7. Summary
    UBI   AU000000UBI2

UNIVERSAL BIOSENSORS, INC.

(UBI)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Universal Biosensors : Update - Coagulation Business Update

10/08/2020 | 03:30am EST

Universal Biosensors Inc

ARBN 121 559 993

1 Corporate Avenue

Rowville VIC 3178

Australia

Telephone +61 3 9213 9000

Facsimile +61 3 9213 9099

Email info@universalbiosensors.com

www.universalbiosensors.com

8 October 2020

UBI appoints its first Coagulation Distribution partner in Europe & appoints European head for Coagulation business

Universal Biosensors, Inc. (ASX Code: UBI) is pleased to announce the appointment of Promedeus s.r.o., as its new distribution partner in Czech Republic and Slovak Republic for Xprecia Stride products. The distribution agreement is for five years and terminates in July 2025.

The deal includes first year forecast sales from Promedeus of 30,000 Strips and 200 Xprecia Stride Analyzers.

UBI has already received the first order for product which has recently been delivered.

Mr John Sharman, CEO of UBI said: "The appointment of Promedeus as our distribution partner marks the first time UBI has been in a position to directly promote and sell Xprecia Stride product anywhere in the world. This is a result of the deal done with Siemen's Healthineers towards the end of 2019 to buy back the global distribution rights for Xprecia Stride product."

Mr Sharman said: "In addition to the new distribution deal, UBI has appointed a senior European based executive to take charge of our coagulation business and grow sales. There are more than 3,500 Xprecia Stride analyzers in use throughout Europe which we plan to leverage to deliver sales to UBI."

Authorised for release by the Board of Universal Biosensors, Inc.

Enquiries:

John Sharman

Craig Coleman

Chief Executive Officer

Chairman

+61 (0) 414 440 680

+61 (0) 401 990 472

Universal Biosensors Inc

ARBN 121 559 993

1 Corporate Avenue

Rowville VIC 3178

Australia

Telephone +61 3 9213 9000

Facsimile +61 3 9213 9099

Email info@universalbiosensors.com

www.universalbiosensors.com

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to

http://www.universalbiosensors.com.

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), food and drink and agriculture.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Universal Biosensors Inc. published this content on 08 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 October 2020 07:29:07 UTC


© Publicnow 2020
All news about UNIVERSAL BIOSENSORS, INC.
01/18Universal Biosensors Unveils Sentia Malic Acid Test for Wine Market
MT
01/17Universal Biosensors, Inc. Announces the Launch of the Sentia Malic Acid Test into the ..
CI
2021Universal Biosensors Enters Deal to Commercialize New COVID-19 Detection Test
MT
2021Universal Biosensors, Inc. Signs Deal to Commercialise SARS-CoV-2 N-Protein Test
CI
2021UNIVERSAL BIOSENSORS : Application for quotation of securities - UBI
PU
2021UNIVERSAL BIOSENSORS : Application for quotation of securities - UBI
PU
2021Application for quotation of securities - UBI
PU
2021Universal Biosensors Enters Master Collaboration Deal With US Cancer Research Institute
MT
2021Universal Biosensors, Mayo Clinic Team Up for Multiple Projects
MT
2021Universal Biosensors, Inc. Signs Master Collaboration Agreement with Mayo Clinic
CI
More news
Financials
Sales 2020 3,20 M 2,30 M 2,30 M
Net income 2020 -7,64 M -5,49 M -5,49 M
Net cash 2020 19,4 M 13,9 M 13,9 M
P/E ratio 2020 -10,1x
Yield 2020 -
Capitalization 164 M 118 M 117 M
EV / Sales 2019 0,51x
EV / Sales 2020 18,1x
Nbr of Employees 60
Free-Float 80,2%
Chart UNIVERSAL BIOSENSORS, INC.
Duration : Period :
Universal Biosensors, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UNIVERSAL BIOSENSORS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
John Stewart Sharman Chief Executive Officer
Salesh Balak Chief Financial Officer
Craig Evan Coleman Non-Executive Chairman
Luke Cossins Head-Research & Development
Nicholas Bliesner Head-Operations
Sector and Competitors
1st jan.Capi. (M$)
UNIVERSAL BIOSENSORS, INC.-7.07%118
THERMO FISHER SCIENTIFIC-13.03%228 678
DANAHER CORPORATION-14.76%200 403
INTUITIVE SURGICAL, INC.-24.98%96 286
SIEMENS HEALTHINEERS AG-7.72%77 272
EDWARDS LIFESCIENCES CORPORATION-13.05%70 331